Innovative Treatment PotentialNemvaleukin is a highly differentiated IL-2 fusion protein that blocks adverse event seen from this drug class, stops proliferation of immune dampening T cell types and activates tumor killing NK and T cells.

Positive Outlook For Mucosal MelanomaThe company remains on track for data updates from Phase 2 ARTISTRY-6 in mucosal melanoma, with a focus on positive outcomes.

Potential New OpportunityMural's next catalyst is Phase 2 mucosal melanoma data, potentially providing a new opportunity for success.

Bears Say

Clinical Trial DiscontinuationMURA is discontinuing nemvaleukin's development in platinum-resistant ovarian cancer (PROC).

Missed Primary EndpointA review of the topline data from ARTISTRY-6 cohort showed the primary endpoint was not achieved.

Workforce ReductionThe company will undertake a reduction in its employee workforce of ~90%.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

3.32% Insiders

7.61% Mutual Funds

<0.01% Other Institutional Investors

83.96% Public Companies and

Individual Investors

Detailed Ownership Overview >

MURA FAQ

What was Mural Oncology Plc’s price range in the past 12 months?

Mural Oncology Plc lowest stock price was $0.95 and its highest was $4.74 in the past 12 months.

What is Mural Oncology Plc’s market cap?

Mural Oncology Plc’s market cap is $42.31M.

When is Mural Oncology Plc’s upcoming earnings report date?

Mural Oncology Plc’s upcoming earnings report date is Aug 19, 2025 which is in 25 days.

How were Mural Oncology Plc’s earnings last quarter?

Mural Oncology Plc released its earnings results on May 14, 2025. The company reported -$1.93 earnings per share for the quarter, beating the consensus estimate of -$1.987 by $0.057.

Is Mural Oncology Plc overvalued?

According to Wall Street analysts Mural Oncology Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mural Oncology Plc pay dividends?

Mural Oncology Plc does not currently pay dividends.

What is Mural Oncology Plc’s EPS estimate?

Mural Oncology Plc’s EPS estimate is -1.

How many shares outstanding does Mural Oncology Plc have?

Mural Oncology Plc has 17,268,880 shares outstanding.

What happened to Mural Oncology Plc’s price movement after its last earnings report?

Mural Oncology Plc reported an EPS of -$1.93 in its last earnings report, beating expectations of -$1.987. Following the earnings report the stock price went down -3.759%.

Which hedge fund is a major shareholder of Mural Oncology Plc?

Currently, no hedge funds are holding shares in MURA

Mural Oncology Plc Stock Smart Score

Underperform

Fundamentals

Return on Equity

-76.27%

Trailing 12-Months

Asset Growth

-49.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mural Oncology Plc

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.